(Q38411245)

2 September 2017

Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study (English)

1 reference

2 September 2017

Kimberly Spencer

1

1 reference

2 September 2017

Kelly Colvin

2

1 reference

2 September 2017

Brad Braunecker

3

1 reference

2 September 2017

Marcia Brackman

4

1 reference

2 September 2017

Joyce Ripley

5

1 reference

2 September 2017

Paul Hines

6

1 reference

2 September 2017

Zachary Skrivanek

7

1 reference

2 September 2017

Brenda Gaydos

8

1 reference

2 September 2017

Mary Jane Geiger

9

1 reference

2 September 2017

1 November 2012

1 reference

Journal of Diabetes Science and Technology

2 September 2017

1 reference

2 September 2017

6

1 reference

2 September 2017

6

1 reference

2 September 2017

1296-1304

1 reference

An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics

2 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570869

PubMed Central

reference URL

Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570869

PubMed Central

reference URL

10.1177/193229681200600608

31 August 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

2 September 2017

1 reference